Cent Eur J Public Health 2009, 17(4):223-230 | DOI: 10.21101/cejph.a3538

Hypertension and Common Complications - Analysis of the Ambulatory Treatment Cost

Anna D. Ivanova, Guenka I. Petrova
Department of Social Pharmacy, Faculty of Pharmacy at the Medical University, Sofia, Bulgaria

Aim: Retrospective analysis of the prescribing practice and cost of ambulatory treatment of hypertension and its common complications - heart failure, sequelae of cerebrovascular disease, and angina pectoris.

Methods: Analysis of 3,240 reimbursable ambulatory prescriptions for hypertension, heart failure, sequelae of cerebrovascular disease and angina pectoris according to the complexity of the therapy and frequency of the prescribed medicines. Modeling and calculation of the expected monthly cost for outpatient therapy by using the "decision tree model". Sensitivity analysis is performed within the ±30% interval.

Results: 65% of the prescription were for the hypertension, and 35% for the observed complications. 1,297 prescriptions for hypertension include one medicine, 647 include two medicines, and only 8% of prescriptions were for three medicines. ACE inhibitors have been prescribed in 41% of all hypertension prescriptions, followed by beta-blockers (19%), Ca channel blockers (16%), diuretics (15%) etc. The prescriptions for hypertension complications are more diverse as therapeutic groups. The expected monthly cost of prescribed medicines per patient with hypertension alone is 6.90 € and in case of complications it is 10.71 € according to the prevalence of the complexity of therapy, and weighted monthly cost of medicines. The overall ambulatory cost is expected to be around 148 million € per year for near 1.5 million patients with 44% reimbursement. The cost of the therapy is sensitive more to changes in the medicine's prices than to its complexity.

Conclusion: This study is a first step in providing information for evidence-based cost containment measures or policy decisions at ambulatory level in Bulgaria and for the assessment of the share of complications' therapy on the overall hypertension cost.

Keywords: hypertension cost, prescription habits, angina pectoris cost, heart failure cost, stroke cost, cost modeling

Received: December 12, 2008; Published: December 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ivanova AD, Petrova GI. Hypertension and Common Complications - Analysis of the Ambulatory Treatment Cost. Cent Eur J Public Health. 2009;17(4):223-230. doi: 10.21101/cejph.a3538. PubMed PMID: 20377054.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005 Jan 15-21;365(9455):217-23. Go to original source...
    2. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA. 2003 May 14;289(18):2363-9. Go to original source... Go to PubMed...
    3. Lloyd A, Schmieder C, Marchant N. Financial and health costs of uncontrolled blood pressure in the United Kingdom. Pharmacoeconomics. 2003;21 Suppl 1:33-41. Go to original source... Go to PubMed...
    4. Hansson L, Lloyd A, Anderson P, Kopp Z. Excess morbidity and cost of failure to achieve targets for blood pressure control in Europe. Blood Press. 2002;11(1):35-45. Go to original source... Go to PubMed...
    5. Thomson R, Greenaway J, Chinn DJ, Wood R, Rodgers H. The impact of implementing national hypertension guidelines on prevalence and workload in primary care: a population-based survey of older people. J Hum Hypertens. 2005 Sep;19(9):683-9. Go to original source... Go to PubMed...
    6. World Health Organization [homepage on the Internet]. Core health indicators [cited 2009 Jun 4]. Available from: http://www.who.int/whosis/database/core/core_select_process.cfm.
    7. National Statistic Institute of Bulgaria [homepage on the Internet]. Reasons for death 2007 [cited 2009 Jun 4]. Available from: http://www.nsi.bg/SocialActivities/Health.htm. (In Bulgarian.)
    8. Sans S, Kesteloot H, Kromhout D; Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. The burden of cardiovascular diseases mortality in Europe. Eur Heart J. 1997 Aug;18(8):1231-48. Go to original source...
    9. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA project: Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation. 1994 Jul;90(1):583-612. Go to original source...
    10. National Health Insurance Fund [homepage on the Internet]. An annual report for the National Health Insurance Fund activities for 2004 [cited 2009 Jun 4].Available from: http://www.nhif.bg/downloads/Otchet_2004.pdf. (In Bulgarian.)
    11. Johannesson M, Le Lorier J. How to assess the economics of hypertension control programmes. J Hum Hypertens. 1996 Feb;10 Suppl 1: S93-4.
    12. Marković BB, Kranjcević K, Reiner Z, Blazeković SN, Spehar SS. Drug therapy of cardiovascular risk factors: guidelines versus reality in primary health care service. Croat Med J. 2005 Dec;46(6):984-9.
    13. Kwaśniewska M, Bielecki W, Drygas W. Sociodemographic and clinical determinants of quality of life in urban population of Poland. Cent Eur J Public Health. 2004 Jun;12(2):63-8.
    14. Panagiotakos DB, Pitsavos Ch, Chrysohoou Ch, Stefanadis Ch, Toutouzas P. The role of traditional mediterranean type of diet and lifestyle, in the development of acute coronary syndromes: preliminary results from CARDIO 2000 study. Cent Eur J Public Health. 2002 Jun;10(12):11-5.
    15. Kopczyński J, Wojtyniak B, Goryński P, Lewandowski Z. The future of chronic diseases. Cent Eur J Public Health. 2001 Feb;9(1):3-13.
    16. Tibi-Levy Y, de Pouvourville G, Westerloppe J, Bamberger M. The cost of treating high blood pressure in general practice in France. Eur J Health Econ. 2008 Aug;9(3):229-36. Go to original source... Go to PubMed...
    17. Marques-Vidal P, Montaye M, Ruidavets JB, Amouyel P, FerrieÌres J. Evolution and cost trends of antihypertensive and hypolipidaemic drug treatment in France. Cardiovasc Drugs Ther. 2003 Mar;17(2):175-89. Go to original source... Go to PubMed...
    18. Shiner T, Simons L, Parkinson H, KhanbhaiA, Karthikeyan VJ, Nandhara G, et al. The financial cost of optimising blood pressure control. J Hum Hypertens. 2005 Jan;19(1):83-4. Erratum in: J Hum Hypertens. 2005 Oct;19(10):849. Go to original source... Go to PubMed...
    19. Degli Esposti E, Berto P, Ruffo P, Buda S, Degli Esposti L, Sturani A; Pandora Study Group. The PANDORA project: results of the cost of illness analysis. J Hum Hypertens. 2001 May;15(5):329-34. Go to original source... Go to PubMed...
    20. ArredondoA, ZúńigaA. Epidemiologic changes and economic burden of hypertension in LatinAmerica: evidence from Mexico.Am J Hypertens. 2006 Jun;19(6):553-9. Go to original source...
    21. Wilson TW, Chockalingam A, Quest DW. Pharmacoeconomics of hypertension control: basic principles of economic evaluation. J Hum Hypertens. 1996 Feb;10 Suppl 2:S19-22.
    22. Linjer E, Hedner T, Jönsson B, Ekbom T, Lindholm LH, Dahlöf B, et al; Stop-2 Hypertension Group. Cost analysis of different pharmacological treatment strategies in elderly hypertensives. Blood Press. 2005;14(2):107- 13. Go to original source... Go to PubMed...
    23. Elliott WJ. The economic impact of hypertension. J Clin Hypertens (Greenwich). 2003 May-Jun;5(3 Suppl 2):3-13. Go to original source...
    24. Chen K, Chiou CF, Plauschinat CA, Frech F, Harper A, Dubois R. Patient satisfaction with antihypertensive therapy. J Hum Hypertens. 2005 Oct;19(10):793-9. Go to original source... Go to PubMed...
    25. AdigunAQ, Ishola DA,AkintomideAO,AjayiAA. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmacoeconomics of old and newer antihypertensive drugs. J Hum Hypertens. 2003 Apr;17(4):277-85. Go to original source... Go to PubMed...
    26. Wang YR, Alexander GC, Stafford RS. Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch Intern Med. 2007 Jan 22;167(2):141-7. Erratum in: Arch Intern Med. 2007 Apr 9;167(7):648. Go to original source... Go to PubMed...
    27. Ambrosioni E. Pharmacoeconomics of hypertension management: the place of combination therapy. Pharmacoeconomics. 2001;19(4):33747. Go to original source... Go to PubMed...
    28. PalmerA, Chambers S. Disease overview - hypertension. Drugs Context. 2006;2(13):561-72.
    29. Lindholm LH, Carlberg B, Samuelsson O. Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005 Oct 29-Nov 4;366(9496):1545-53. Go to original source... Go to PubMed...
    30. Flack JM, Casciano R, Casciano J, Doyle J, Arikian S, Tang S, et al. Cardiovascular disease costs associated with uncontrolled hypertension. Manag Care Interface. 2002 Nov;15(11): 28-36.
    31. Hodgson TA, Cai L. Medical care expenditures for hypertension, its complications, and its comorbidities. Med Care. 2001 Jun;39(6):599-615. Go to original source... Go to PubMed...
    32. Mehta SS, Wilcox CS, Schulman KA. Treatment of hypertension in patients with comorbidities: results from the study of hypertensive prescribing practices (SHyPP). Am J Hypertens. 1999 Apr;12(4 Pt 1):333-40. Go to original source...
    33. World Health Organization [homepage on the Internet]. International Statistical Classification of Diseases and Related Health Problems. 10th Revision [cited 2007 Jun 11]. Available from: www.who.int/classifications/apps/icd/icd10online/navi.htm..
    34. National health insurance fund [homepage on the Internet].Amendment 2 to " Instruction for usage of drug list of NHIF (Amendment 11 of National Agreement 2006, State Gazette 106/2005) in force from 01 September 2006-work version for-pharmacy [cited 2009 Jun 4]. Available from: http://www.nhif.bg/bg/default.phtml?w=800&h=570. (In Bulgarian.)
    35. Elliot R, Payne K. Essentials of economic evaluation in healthcare. 1st ed. London: Pharmaceutical Press; 2005.
    36. World Health Organization [homepage on the Internet]. European Health forAll database (HFA-DB) [cited 2009 Jun 4].Available from:http://data. euro.who.int/hfadb/.
    37. Gerbrandt KR,Yedinak KC. Formulary management of ACE inhibitors. Pharmacoeconomics. 1996 Dec;10(6):594-613. Go to original source... Go to PubMed...
    38. Nordmann AJ, Krahn M, Logan AG, Naglie G, Detsky AS. The cost effectiveness of ACE inhibitors as first-line antihypertensive therapy. Pharmacoeconomics. 2003;21(8):573-85. Go to original source... Go to PubMed...
    39. Payne KA, Caro JJ. Evaluating the true cost of hypertension management: evidence from actual practice. Expert Rev Pharmacoecon Outcomes Res. 2004 Apr;4(2):179-87. Go to original source... Go to PubMed...
    40. International Healthcare and Health Insurance Institute [homepage on the Internet]. Bulgaria. Review and strategy for National Healthcare. Sofia, September 2004 [cited 2009 Jun 4]. Available from: http://www.zdrave.net/document/services/health_policy/Health%20strategy_05-10_BG.pdf. (In Bulgarian.)

    Return to the content